Tags

Type your tag names separated by a space and hit enter

Ulerythema ophryogenes: updates and insights.

Abstract

Ulerythema ophryogenes is a rare cutaneous atrophic disorder that occasionally is associated with Noonan syndrome, de Lange syndrome, Rubinstein-Taybi syndrome, and cardiofaciocutaneous (CFC) syndrome. Often presenting in pediatric patients, the pathogenesis of ulerythema ophryogenes remains unclear, though several genetic causes have been suggested. Treatment recommendations remain anecdotal, but clearance has been noted as the patient ages. Although topical agents have been the mainstay of therapy, recent advancement in laser intervention for treatment of ulerythema ophryogenes is promising.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    , , ,

    Department of Dermatology, Rutgers New Jersey Medical School, Medical Science Building, H-576, Newark, NJ 07103, USA. roschwar@cal.berkeley.edu.

    Source

    Cutis 93:2 2014 Feb pg 83-7

    MeSH

    Abnormalities, Multiple
    Anti-Inflammatory Agents
    Child
    Darier Disease
    De Lange Syndrome
    Disease Progression
    Ectodermal Dysplasia
    Eyebrows
    Facies
    Failure to Thrive
    Heart Defects, Congenital
    Humans
    Intense Pulsed Light Therapy
    Keratolytic Agents
    Lasers, Dye
    Low-Level Light Therapy
    Noonan Syndrome
    Rubinstein-Taybi Syndrome
    Triamcinolone

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    24605344

    Citation

    Morton, Christopher M., et al. "Ulerythema Ophryogenes: Updates and Insights." Cutis, vol. 93, no. 2, 2014, pp. 83-7.
    Morton CM, Bhate C, Janniger CK, et al. Ulerythema ophryogenes: updates and insights. Cutis. 2014;93(2):83-7.
    Morton, C. M., Bhate, C., Janniger, C. K., & Schwartz, R. A. (2014). Ulerythema ophryogenes: updates and insights. Cutis, 93(2), pp. 83-7.
    Morton CM, et al. Ulerythema Ophryogenes: Updates and Insights. Cutis. 2014;93(2):83-7. PubMed PMID: 24605344.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Ulerythema ophryogenes: updates and insights. AU - Morton,Christopher M, AU - Bhate,Chinmoy, AU - Janniger,Camila K, AU - Schwartz,Robert A, PY - 2014/3/8/entrez PY - 2014/3/8/pubmed PY - 2014/10/30/medline SP - 83 EP - 7 JF - Cutis JO - Cutis VL - 93 IS - 2 N2 - Ulerythema ophryogenes is a rare cutaneous atrophic disorder that occasionally is associated with Noonan syndrome, de Lange syndrome, Rubinstein-Taybi syndrome, and cardiofaciocutaneous (CFC) syndrome. Often presenting in pediatric patients, the pathogenesis of ulerythema ophryogenes remains unclear, though several genetic causes have been suggested. Treatment recommendations remain anecdotal, but clearance has been noted as the patient ages. Although topical agents have been the mainstay of therapy, recent advancement in laser intervention for treatment of ulerythema ophryogenes is promising. SN - 2326-6929 UR - https://www.unboundmedicine.com/medline/citation/24605344/Ulerythema_ophryogenes:_updates_and_insights L2 - http://www.cutis.com/the-publication/past-issues-single-view/ulerythema-ophryogenes-updates-and-insights/2de6f3583c85cd1ccf40aad14a2ef178.html DB - PRIME DP - Unbound Medicine ER -